Protecting Drug Safety - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Protecting Drug Safety

Pharmaceutical Technology Europe
Volume 26, Issue 8, pp. 42
PharmTech Europe 25th Anniversary
DSGpro/Getty Images;
Art direction: Dan Ward

Packaging Provides Safety and Security

Packaging machinery suppliers describe how changes in regulations have driven developments in packaging and look ahead to coming challenges.

In the past 10 years, safety issues have become increasingly important in pharmaceutical packaging. Needle shielding is one example. The United States government issued the “Needlestick Safety and Prevention Act” for the protection of medical personnel against needlestick injuries in 2000, and an EU directive (2010/32/EU) was published in 2010. A variety of solutions have been developed, from a functional label with integrated needle shield (i.e., needle trap) to more complex safety devices with a retraction mechanism for the injection needle. We, as manufacturers of special machinery, must take up such new requirements and develop new solutions for the production process.

Pharmaceutical Technology Europe
25th Anniversary Issue

Related Content

Serialisation, Aggregation and Authentication

Another challenge with regard to drug safety is the control of counterfeit drugs. The EU has issued the so-called “Counterfeit Directive” (2011/62/EU) to protect the consumer against drug counterfeits. The directive demands, among other requirements, a tamper-evident closure for prescription pharmaceuticals by which one can see if a package has already been opened or manipulated.

To safeguard the channel of distribution against counterfeit drugs, drug packages are serialised by imprinting a two-dimensional code. Besides an incidental serial number, the code can also accommodate variable data such as the date of production and batch number. The objective is to store the data of the drugs in a central database and to monitor the distribution chain from the manufacturer through the wholesale trade and the pharmacy to the final consumer.

The race between pharmaceutical manufacturers and counterfeiters will keep going on in the future, because sooner or later every safety feature can be copied. Ideas are needed from the packaging industry so that packages can be marked with new safety features, such as the use of DNA markers on folding boxes or plastic sleeves for vials that are covered by a perforated, adhesive label and irreversibly destroyed upon opening. Packaging-machine manufacturers will take up these new ideas and continue to develop new solutions.

  Rüdiger Manthey
Rüdiger Manthey

About the Author
Rüdiger Manthey is a pharmacist for Pharma Compliance at Bausch+Ströbel Maschinenfabrik Ilshofen.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here